Thursday, August 25, 2022

Aristea Therapeutics Names New Board Members

San Diego-based Aristea Therapeutics said this week that it has named two new members to its board of directors. According to the company, it has appointed both Mark Gergen and Daniel O'Connell, M.D., Ph.D., to its Board of Directors, and Michael S. Vincent, M.D. Ph.D. as an observer. O'Connell represents Novo Holdings, and Vincent represents Pfizer. Gergan is the CEo of Poseida Therapeutics, and also served at Halozyme Therapeutics, Mirati Therapeutics, and Amylin Pharmaceuticals. Vincent is Senior Vice President and Chief Scientific Officer of the Inflammation and Immunology Research Unit at Pfizer.